Novelix Pharmaceuticals (BOM:536565) ROCE %: 9.71% (As of Mar. 2026)


BOM:536565 Novelix Pharmaceuticals Ltd BOM:536565
73 GF Score
Price ₹77.97
GF Value ₹144.32
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Novelix Pharmaceuticals ROCE %?

Novelix Pharmaceuticals BOM:536565 -0.80% 73 ROCE % is 9.71% as of Mar. 2026. GuruFocus rates BOM:536565 with a GF Score™ of 73/100 and a GF Value™ of ₹144.32 (Possible Value Trap). The stock has 8 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Novelix Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was 9.71%.

Novelix Pharmaceuticals  (BOM:536565) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Novelix Pharmaceuticals ROCE % Related Terms

Novelix Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Novelix Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novelix Pharmaceuticals ROCE % Chart

Novelix Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.05 -7.95 0.31 0.99 9.96

Novelix Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.80 3.86 11.23 20.04 9.71
BOM:536565
73GF Score
Novelix Pharmaceuticals Ltd BOM:536565
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novelix Pharmaceuticals ROCE % Calculation

Novelix Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=34.043/( ( (272.065 - 96.672) + (924.233 - 416.13) )/ 2 )
=34.043/( (175.393+508.103)/ 2 )
=34.043/341.748
=9.96 %

Novelix Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=49.316/( ( (0 - 0) + (924.233 - 416.13) )/ 1 )
=49.316/( ( 0 + 508.103 )/ 1 )
=49.316/508.103
=9.71 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 9.71% mean?
Novelix Pharmaceuticals (BOM:536565) has a ROCE % of 9.71% as of Mar. 2026.
Is Novelix Pharmaceuticals' ROCE % too high?
Novelix Pharmaceuticals' current ROCE % is 9.71%. The Medical Distribution industry median ROCE % is 8.92. Novelix Pharmaceuticals' value of 9.71% is 8.9% above this industry median. Overall, Novelix Pharmaceuticals has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Novelix Pharmaceuticals' ROCE % compare to MCK and CAH?
Novelix Pharmaceuticals' ROCE % of 9.71% can be compared against companies in the Medical Distribution industry. The industry median ROCE % is 8.92. Novelix Pharmaceuticals' value of 9.71% is 8.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Distribution company?
The median ROCE % among Medical Distribution companies is 8.92, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novelix Pharmaceuticals's current ROCE % of 9.71% is 8.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median ROCE % is 8.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novelix Pharmaceuticals's current ROCE % is 9.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novelix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Novelix Pharmaceuticals (BOM:536565) is currently considered Possible Value Trap. The stock's GF Value™ is ₹144.32, compared to a current price of ₹77.97 — trading 46% below its estimated fair value. The current ROCE % is 9.71% and 8.9% above the Medical Distribution industry median of 8.92. Novelix Pharmaceuticals' overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Novelix Pharmaceuticals (BOM:536565), the current ROCE % is 9.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novelix Pharmaceuticals (BOM:536565) Overvalued in 2026?

Based on GuruFocus' analysis, Novelix Pharmaceuticals stock appears to be undervalued. The current stock price of ₹77.97 is trading 46% below its estimated GF Value™ of ₹144.32. GuruFocus considers Novelix Pharmaceuticals to be Possible Value Trap.

Key valuation signals for BOM:536565:

  • ROCE %: 9.71%
  • GF Value™: ₹144.32 vs. price of ₹77.97 (46% below fair value)
  • GF Score™: 73/100 with 8 warning signs
  • Industry Position: 8.9% above the Medical Distribution median

No single metric tells the full story. See the BOM:536565 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novelix Pharmaceuticals Business Description

Address Lingapur LA Builders, Amrutha Estates, 6th floor, House no. 3-6-237/610, Himayath nagar, Hyderabad, TG, IND, 500029
Novelix Pharmaceuticals Ltd is into the business of Trading of Pharmaceuticals and related products and is into the business of trading of shares and securities. The company generates majaority of its revenue from the Pharmaceuticals business.
73GF Score

Get the complete analysis for BOM:536565

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹77.97
Price
₹144.32
GF Value